Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248824 | 0.82 | — | — | |
| SCHEMBL8375197 | 0.75 | — | — | |
| SCHEMBL7160307 | 0.73 | — | — | |
| SCHEMBL7870976 | 0.73 | — | — | |
| SCHEMBL16552631 | 0.73 | ALDH1A1 (0.31) | ALDH1A1TSHR | |
| SCHEMBL7872900 | 0.72 | — | — | |
| SCHEMBL20360185 | 0.69 | — | — | |
| SCHEMBL21131283 | 0.69 | — | — | |
| SCHEMBL7872881 | 0.69 | — | — | |
| SCHEMBL7217395 | 0.67 | ALDH1A1 (0.39) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250846-A1 | Non-peptide GnRH agents, pharmaceutical compositions and methods for their use | ANDERSON MARK B | 2005-11-10 | — | — | US | disclosed |
| EP-1560818-A1 | NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2005-08-10 | — | — | EP | disclosed |
| US-6903132-B2 | Non-peptide GnRH agents, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | CANAN-KOCH STACIE (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2003106446-A1 | NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| EP-1336600-A2 | Dimer-selective RXR modulators and methods for their use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6545049-B1 | E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof | LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-08 | — | — | US | disclosed |
| WO-2000026173-A1 | NOVEL RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (DE) | 2000-05-11 | — | — | WO | disclosed |
| US-6005007-A | SKIN DISORDERS | LIGAND PHARMACEUTICALS INCORPORATED | 1999-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250846-A1 | Non-peptide GnRH agents, pharmaceutical compositions and methods for their use | GNRHR, LHCGR, FSHR | ALDH1A1 4773/4885TSHR 162/4885 |
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | RXRG, RXRB, RXRA | ALDH1A1 4172/4885TSHR 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.